PLATINUM-SENSITIVE OVARIAN CARCINOMA
Clinical trials for PLATINUM-SENSITIVE OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-SENSITIVE OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for PLATINUM-SENSITIVE OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced cancers with DNA repair flaws: PARP inhibitor trial opens
Disease control Recruiting nowThis study tests the drug talazoparib in adults with advanced solid tumors (like breast, prostate, ovarian, pancreatic, or stomach cancer) that have certain gene changes affecting DNA repair. The drug blocks a protein called PARP, which cancer cells need to fix their DNA, potenti…
Matched conditions: PLATINUM-SENSITIVE OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New hope for recurrent ovarian cancer: triple drug attack launched
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with specific types of recurrent ovarian, fallopian tube, or peritoneal c…
Matched conditions: PLATINUM-SENSITIVE OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:50 UTC